other material
confidence high
sentiment neutral
materiality 0.55
Lixte exchanges 2,700 Series C preferred for 700K common shares and 20% of Liora subsidiary
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- Orbit Capital Inc. exchanged 2,700 Series C Preferred shares for 700,000 Lixte common shares and 200 ordinary shares of Liora (20% of Liora).
- Upon closing, all Series C Preferred shares were cancelled and no longer outstanding.
- Lixte retained 800 ordinary shares of Liora after the exchange.
- Transaction was exempt from registration under Section 4(a)(2) and Regulation D.